Bristol-Myers Squibb Earnings In Retrospect: Down 3.6% in the Last 16 Days (BMY) Financial News Network Online The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. By Adrienne Chilton. |
